The End Is Nigh For Mylan, But How Different Will The New Company Be?

Mylan will be merged into a new company with Pfizer’s Upjohn, closing the chapter on a generic drug powerhouse that will be remembered as much for scandal as success.

The End handwrite title on red round background. Old movie circle ending screen. Vector illustration - Vector

Mylan NV has a long history in the generic pharmaceutical market, maintaining its independence while plenty of other mid-sized specialty generic peers were absorbed into larger corporations. Now the Mylan story draws to an end with the company's planned merger with Pfizer Inc.'s off patent Upjohn business and the creation of a new company.

Mylan's evolution into one of the top generic drug companies in the world has been a roller coaster of highs and lows

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

06 May 2025

• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

05 May 2025

• By Joseph Haas

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

05 May 2025

• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.